Ervaren John Potthoff in raad van bestuur SynteractHCR
SAN DIEGO–(BUSINESS WIRE)– SynteractHCR, een toonaangevend bedrijf in uitbestede onderzoeksdiensten, heeft bekendgemaakt dat de ervaren John Potthoff per direct toetreedt tot zijn raad van bestuur. Potthoff kan bogen op brede ervaring in operationele zaken, business development en leidinggeven, die hij heeft opgedaan gedurende zijn 25-jarige carrière in klinische ontwikkeling.
Potthoff is oprichter en CEO van Elligo Health Research, een toonaangevende provider van infrastructuur voor klinisch onderzoek die zich ten doel heeft gesteld klinisch-wetenschappelijke processen. Daarvoor werkte hij als CEO bij Theorem Clinical Research en als operationeel bestuurder bij INC Resears, waar bij met succes bijdroeg aan de indrukwekkende groei van beide onderzoeksdienstverleners.
CRO Industry Veteran John Potthoff Joins SynteractHCR Board of Directors
SAN DIEGO–(BUSINESS WIRE)– SynteractHCR, a leading full-service contract research organization (CRO), announced the appointment of industry veteran John Potthoff to its Board of Directors, effective immediately. Potthoff draws on extensive operational, business development and leadership experience derived through his 25-year career dedicated to clinical development.
Potthoff is a founder and CEO of Elligo Health Research, a leading clinical research infrastructure provider whose mission is to redefine the clinical trial process. Prior to this, he served as CEO of Theorem Clinical Research and COO of INC Research, having successfully contributed to the impressive growth of both CROs. In 2000 he founded and was CEO of Tanistry, a CNS focused CRO, which was acquired by INC Research. He currently sits on the Board of Directors for Chesapeake IRB and previously served as a member of the Board of Directors for Chiltern.
“I have had the pleasure of working directly with John in the past. He is both a respected business leader and an experienced board member in our industry,” said Steve Powell, CEO of SynteractHCR. “Drawing on his years of experience as a CRO executive, industry leader and now CEO of a company that implements new approaches to clinical trial conduct, John will provide fresh insights and counsel invaluable to SynteractHCR and our customers. I am delighted John has agreed to join our Board.”
“We have known John for over 10 years and have seen how he has played a leadership role in building value at INC Research and Theorem,” added Ramsey Frank, partner and co-founder of Amulet Capital. “We welcome John’s addition to the board and are confident his industry acumen will help us build on SynteractHCR’s leading market position and continue to advance the company’s success.”
About SynteractHCR
With 800 staff members across 21 countries, SynteractHCR is an international full-service contract research organization with a successful three-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and in more than 60 countries, offering broad therapeutic expertise, with notable depth in oncology, immunotherapy, CNS and infectious disease, among other indications. With its “Shared Work – Shared Vision” philosophy, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171025005332/en/
Contacts
For SynteractHCR
Nikki Sachman, 760-230-2424
nikki@clearpointagency.com